Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Opexa Therapeutics, Inc. (OPXA) Starts Presentation at 2015 Marcum MicroCap Conference

Posted on May 28, 2015 by MissionIR

Opexa Therapeutics is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The company’s leading therapy candidate, Tcelna®, is in a phase 2b clinical development program for the treatment of secondary progressive MS. For more information, visit the company’s website at www.opexatherapeutics.com.

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.